^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ER D538G

    i
    Entrez ID:
    2099
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINE 1) (NCT03781063)
    Phase 2
    Sermonix Pharmaceuticals Inc.
    Active, not recruiting
    Last update posted :
    04/18/2024
    Initiation :
    09/20/2019
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    HER-2 • ER
    |
    HER-2 negative • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C
    |
    fulvestrant • Fablyn (lasofoxifene)
    Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study (NCT04256941)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    04/16/2024
    Initiation :
    05/31/2019
    Primary completion :
    09/22/2023
    Completion :
    09/22/2023
    ER • PGR
    |
    ER positive • HR positive • ER mutation • ER Y537S • ER D538G • ESR1 mutation
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole
    Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer (H3B-6545-A001-101) (NCT03250676)
    Phase 1/2
    Eisai Inc.
    Completed
    Last update posted :
    12/25/2023
    Initiation :
    08/17/2017
    Primary completion :
    10/26/2023
    Completion :
    10/26/2023
    HER-2 • ER
    |
    ER positive • HER-2 negative • ER Y537S • ER D538G • ESR1 mutation
    |
    H3B-6545
    The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer (NCT03202862)
    Phase 2
    Fudan University
    Unknown status
    Last update posted :
    06/29/2017
    Initiation :
    07/01/2017
    Primary completion :
    06/01/2019
    Completion :
    08/01/2019
    ER • PGR
    |
    ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER Y537C
    |
    fulvestrant